Your browser doesn't support javascript.
loading
Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom.
Whitaker, Heather; Findlay, Beth; Zitha, Jana; Goudie, Rosalind; Hassell, Katie; Evans, Josie; Kalapotharakou, Panoraia; Agrawal, Utkarsh; Kele, Beatrix; Hamilton, Mark; Moore, Catherine; Byford, Rachel; Stowe, Julia; Robertson, Chris; Couzens, Anastasia; Jamie, Gavin; Hoschler, Katja; Pheasant, Kathleen; Button, Elizabeth; Quinot, Catherine; Jones, Tim; Anand, Sneha; Watson, Conall; Andrews, Nick; de Lusignan, Simon; Zambon, Maria; Williams, Christopher; Cottrell, Simon; Marsh, Kimberly; McMenamin, Jim; Lopez Bernal, Jamie.
Afiliação
  • Whitaker H; Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK.
  • Findlay B; Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
  • Zitha J; Public Health Wales Communicable Disease Surveillance Centre and Vaccine Preventable Disease Programme, Public Health Wales NHS Trust, Cardiff, UK.
  • Goudie R; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Hassell K; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
  • Evans J; Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
  • Kalapotharakou P; Public Health Wales Communicable Disease Surveillance Centre and Vaccine Preventable Disease Programme, Public Health Wales NHS Trust, Cardiff, UK.
  • Agrawal U; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Kele B; Respiratory Virus Unit, UK Health Security Agency, London, UK.
  • Hamilton M; Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
  • Moore C; Wales Specialist Virology Centre, Public Health Wales Microbiology, Cardiff, UHW, Cardiff, UK.
  • Byford R; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Stowe J; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
  • Robertson C; Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
  • Couzens A; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
  • Jamie G; Wales Specialist Virology Centre, Public Health Wales Microbiology, Cardiff, UHW, Cardiff, UK.
  • Hoschler K; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Pheasant K; Respiratory Virus Unit, UK Health Security Agency, London, UK.
  • Button E; Wales Specialist Virology Centre, Public Health Wales Microbiology, Cardiff, UHW, Cardiff, UK.
  • Quinot C; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Jones T; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
  • Anand S; Wales Specialist Virology Centre, Public Health Wales Microbiology, Cardiff, UHW, Cardiff, UK.
  • Watson C; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Andrews N; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
  • de Lusignan S; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
  • Zambon M; Nuffield Department of Primary Care, University of Oxford, Oxford, UK.
  • Williams C; Research and Surveillance Centre, Royal College of General Practitioners, London, UK.
  • Cottrell S; Respiratory Virus Unit, UK Health Security Agency, London, UK.
  • Marsh K; Public Health Wales Communicable Disease Surveillance Centre, Public Health Wales NHS Trust, Cardiff, UK.
  • McMenamin J; Public Health Wales Communicable Disease Surveillance Centre and Vaccine Preventable Disease Programme, Public Health Wales NHS Trust, Cardiff, UK.
  • Lopez Bernal J; Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
Influenza Other Respir Viruses ; 18(5): e13284, 2024 May.
Article em En | MEDLINE | ID: mdl-38773753
ABSTRACT

BACKGROUND:

We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.

METHODS:

A test negative design was used to estimate vaccine effectiveness.

RESULTS:

Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.

CONCLUSIONS:

During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atenção Primária à Saúde / Atenção Secundária à Saúde / Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / Vírus da Influenza A Subtipo H3N2 Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Assunto da revista: VIROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atenção Primária à Saúde / Atenção Secundária à Saúde / Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / Vírus da Influenza A Subtipo H3N2 Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Influenza Other Respir Viruses Assunto da revista: VIROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido